First-line treatment of chronic myeloid leukaemia

Michael O'dwyer

doi:10.1177/2040620710387981

First-line treatment of chronic myeloid leukaemia

Michael O'dwyer

Galway University Hospital

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

1 Citation (Scopus)

Abstract

Since the introduction of imatinib just over a decade ago, there has been a dramatic change in the treatment and prognosis of early chronic phase chronic myeloid leukaemia (CML). This review article focuses on recent advances, culminating in the approval of nilotinib by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed CML in the chronic phase.

Original language	English
Pages (from-to)	15-22
Number of pages	8
Journal	Therapeutic Advances in Hematology
Volume	1
Issue number	1
DOIs	https://doi.org/10.1177/2040620710387981
Publication status	Published - Dec 2010
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

CML
early chronic phase
treatment
tyrosine kinase inhibitor

Access to Document

10.1177/2040620710387981

Cite this

@article{bdbd295258a948baba4437bb4d52378f,

title = "First-line treatment of chronic myeloid leukaemia",

abstract = "Since the introduction of imatinib just over a decade ago, there has been a dramatic change in the treatment and prognosis of early chronic phase chronic myeloid leukaemia (CML). This review article focuses on recent advances, culminating in the approval of nilotinib by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed CML in the chronic phase.",

keywords = "CML, early chronic phase, treatment, tyrosine kinase inhibitor",

author = "Michael O'dwyer",

year = "2010",

month = dec,

doi = "10.1177/2040620710387981",

language = "English",

volume = "1",

pages = "15--22",

journal = "Therapeutic Advances in Hematology",

issn = "2040-6207",

publisher = "SAGE Publications Inc.",

number = "1",

}

TY - JOUR

T1 - First-line treatment of chronic myeloid leukaemia

AU - O'dwyer, Michael

PY - 2010/12

Y1 - 2010/12

N2 - Since the introduction of imatinib just over a decade ago, there has been a dramatic change in the treatment and prognosis of early chronic phase chronic myeloid leukaemia (CML). This review article focuses on recent advances, culminating in the approval of nilotinib by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed CML in the chronic phase.

AB - Since the introduction of imatinib just over a decade ago, there has been a dramatic change in the treatment and prognosis of early chronic phase chronic myeloid leukaemia (CML). This review article focuses on recent advances, culminating in the approval of nilotinib by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed CML in the chronic phase.

KW - CML

KW - early chronic phase

KW - treatment

KW - tyrosine kinase inhibitor

UR - https://www.scopus.com/pages/publications/84993728799

U2 - 10.1177/2040620710387981

DO - 10.1177/2040620710387981

M3 - Article

AN - SCOPUS:84993728799

SN - 2040-6207

VL - 1

SP - 15

EP - 22

JO - Therapeutic Advances in Hematology

JF - Therapeutic Advances in Hematology

IS - 1

ER -

First-line treatment of chronic myeloid leukaemia

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this